Objective: To investigate the relationship between the expression of tumor suppressor in lung cancer-1 (TSLC1) and clinicopathological characteristics of patients with non-muscle-invasive bladder cancer (NMIBC) and evaluate the prognostic significance of TSLC1. Methods: TSLC1 expression in 241 specimens of NMIBC was examined by immunohistochemistry. The correlation between TSLC1 expression and clinicopathological characteristics was evaluated using the chi-square test. The prognostic significance of TSLC1 was analyzed by univariate, multivariate analysis and Kaplan-Meier survival curves. Results: The total negative rate of TSLC1 expression was 47.3% in NMIBC. Decreased expression of TSLC1 was correlated with a higher clinical stage, higher pathological grade, the number of tumors, lager tumor size, tumor recurrence and progression. TSLC1 expression was an independent risk factor for predicting tumor recurrence (p = 0.005) and progression (p < 0.001). Conclusion: Decreased expression of TSLC1 is correlated with the malignancy of NMIBC tissues and low TSLC1 expression may serve as a predictor for bladder cancer recurrence and progression.

Keywords:
TSLC1, Non-muscle-invasive bladder cancer, Recurrence, Progression
1.
Jemal A, Bray F, Center MM, et al: Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2.
Parkin DM: The global burden of urinary bladder cancer. Scand J Urol Nephrol Suppl 2008;218:12-20.
3.
Millán-Rodríguez F, Chéchile-Toniolo G, Salvador-Bayarri J, et al: Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. J Urol 2000;164(3 pt 1):680-684.
4.
Otto T, Krege S, Noll F, et al: Therapy of superficial bladder carcinomas. Urol Int 1999;63:32-39.
5.
Rübben H, Lutzeyer W, Fischer N, et al: Natural history and treatment of low and high risk superficial bladder tumors. J Urol 1988;139:283-285.
6.
Millán-Rodríguez F, Chéchile-Toniolo G, Salvador-Bayarri J, et al: Multivariate analysis of the prognostic factors of primary superficial bladder cancer. J Urol 2000;163:73-78.
7.
Masuda M, Yageta M, Fukuhara H, et al: The tumor suppressor protein TSLC1 is involved in cell-cell adhesion. J Biol Chem 2002;277:31014-31019.
8.
Shingai T, Ikeda W, Kakunaga S, et al: Implications of nectin-like molecule-2/IGSF4/RA175/SgIGSF/TSLC1/SynCAM1 in cell-cell adhesion and transmembrane protein localization in epithelial cells. J Biol Chem 2003;278:35421-35427.
9.
Liang QL, Chen GQ, Li ZY, et al: Function and histopathology of a cell adhesion molecule TSLC1 in cancer. Cancer Invest 2011;29:107-112.
10.
Heller G, Fong KM, Girard L, et al: Expression and methylation pattern of TSLC1 cascade genes in lung carcinomas. Oncogene 2006;25:959-968.
11.
Heller G, Geradts J, Ziegler B, et al: Downregulation of TSLC1 and DAL-1 expression occurs frequently in breast cancer. Breast Cancer Res Treat 2007;103:283-291.
12.
Zhou L, Jiang W, Ren C, et al: Frequent hypermethylation of RASSF1A and TSLC1, and high viral load of Epstein-Barr virus DNA in nasopharyngeal carcinoma and matched tumor-adjacent tissues. Neoplasia 2005;7:809-815.
13.
Steenbergen RD, Kramer D, Braakhuis BJ, et al: TSLC1 gene silencing in cervical cancer cell lines and cervical neoplasia. J Natl Cancer Inst 2004;96:294-305.
14.
Ito T, Shimada Y, Hashimoto Y, et al: Involvement of TSLC1 in progression of esophageal squamous cell carcinoma. Cancer Res 2003;63:6320-6326.
15.
Surace EI, Lusis E, Murakami Y, et al: Loss of tumor suppressor in lung cancer-1 (TSLC1) expression in meningioma correlates with increased malignancy grade and reduced patient survival. J Neuropathol Exp Neurol 2004;63:1015-1027.
16.
Chen K, Wang G, Peng L, et al: CADM1/TSLC1 inactivation by promoter hypermethylation is a frequent event in colorectal carcinogenesis and correlates with late stages of the disease. Int J Cancer 2011;128:266-273.
17.
Zhang J, Ning J, Geng J, et al: Down-regulation of tumor suppressor in lung cancer 1 (TSLC1) expression correlates with poor prognosis in patients with colon cancer. J Mol Histol 2012;43:715-721.
18.
Nakahata S, Saito Y, Marutsuka K, et al: Clinical significance of CADM1/TSLC1/IgSF4 expression in adult T-cell leukemia/lymphoma. Leukemia 2012;26:1238-1246.
19.
You Y, Wang SH, Zhang JF, et al: TSLC1 expression discriminates cutaneous melanomas from dysplastic nevi. Melanoma Res 2012;22:430-435.
20.
Tsujiuchi T, Sugata E, Masaoka T, et al: Expression and DNA methylation patterns of Tslc1 and Dal-1 genes in hepatocellular carcinomas induced by N-nitrosodiethylamine in rats. Cancer Sci 2007;98:943-948.
21.
Lu B, Di W, Wang H, et al: Tumor suppressor TSLC1 is implicated in cell proliferation, invasion and apoptosis in laryngeal squamous cell carcinoma by regulating Akt signaling pathway. Tumour Biol 2012;33:2007-2017.
22.
Liang QL, Wang BR, Li ZY, Chen GQ, Zhou Y: Construction of eukaryotic expression vector of TSLC1 gene. Arch Med Sci 2011;7:579-585.
23.
Liang QL, Wang BR, Li ZY, Chen GQ, Zhou Y: Effect of TSLC1 gene on growth and apoptosis in human esophageal carcinoma Eca109 cells. Arch Med Sci 2012;8:987-992.
24.
Liang QL, Chen GQ, Liu QL, Li ZY, Zhang XN, Zhou Y, Ou WT, Wang BR, Hu LR: Tumor suppressor TSLC1 inhibits growth, proliferation, invasiveness and angiogenesis in nude mice xenografted tumor of Eca109 cells. Int J Clin Exp Med 2014;7:1507-1515.
25.
Shi B, Laudon V, Yu S, et al: E-cadherin tissue expression and urinary soluble forms of E-cadherin in patients with bladder transitional cell carcinoma. Urol Int 2008;81:320-324.
26.
Williams YN, Masuda M, Sakurai-Yageta M, et al: Cell adhesion and prostate tumor-suppressor activity of TSLL2/IGSF4C, an immunoglobulin superfamily molecule homologous to TSLC1/IGSF4. Oncogene 2006;25:1446-1453.
27.
Byrne RR, Shariat SF, Brown R, et al: E-cadherin immunostaining of bladder transitional cell carcinoma, carcinoma in situ and lymph node metastases with long-term followup. J Urol 2001;165:1473-1479.
28.
Casadio V, Molinari C, Calistri D, et al: DNA methylation profiles as predictors of recurrence in non muscle invasive bladder cancer: an MS-MLPA approach. J Exp Clin Cancer Res 2013;32:94.
29.
Sacristan R, Gonzalez C, Fernández-Gómez JM, et al: Molecular classification of non-muscle-invasive bladder cancer (pTa low-grade, pT1 low-grade, and pT1 high-grade subgroups) using methylation of tumor-suppressor genes. J Mol Diagn 2014;16:564-572.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.